Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 281

1.

Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis.

van Galen KPM, Timmer M, de Kleijn P, Leebeek FWG, Foppen W, Schutgens REG, Eikenboom J, Meijer K, Fijnvandraat K, Laros-van Gorkom BAP, Twisk JW, Mauser-Bunschoten EP, Fischer K; WiN Studygroup.

Thromb Haemost. 2018 Oct;118(10):1690-1700. doi: 10.1055/s-0038-1670704. Epub 2018 Oct 1.

PMID:
30273954
2.

Hemophilia B in a female with intellectual disability caused by a deletion of Xq26.3q28 encompassing the F9.

Stoof SCM, Kersseboom R, de Vries FAT, Kruip MJHA, Kievit AJA, Leebeek FWG.

Mol Genet Genomic Med. 2018 Sep 27. doi: 10.1002/mgg3.425. [Epub ahead of print]

3.

Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets.

Rijkers M, Schmidt D, Lu N, Kramer CSM, Heidt S, Mulder A, Porcelijn L, Claas FHJ, Leebeek FWG, Jansen AJG, Jongerius I, Zeerleder SS, Vidarsson G, Voorberg J, de Haas M.

Haematologica. 2018 Sep 27. pii: haematol.2018.201665. doi: 10.3324/haematol.2018.201665. [Epub ahead of print]

4.

Anticoagulant medication errors in hospitals and primary care: a cross-sectional study.

Dreijer AR, Diepstraten J, Bukkems VE, Mol PGM, Leebeek FWG, Kruip MJHA, van den Bemt PMLA.

Int J Qual Health Care. 2018 Aug 25. doi: 10.1093/intqhc/mzy177. [Epub ahead of print]

PMID:
30165484
5.

Positioning extended half-life concentrates for future use: a practical proposal.

Nederlof A, Mathôt RAA, Leebeek FWG, Fijnvandraat K, Fischer K, Cnossen MH; “OPTI-CLOT” study group.

Haemophilia. 2018 Sep;24(5):e369-e372. doi: 10.1111/hae.13588. Epub 2018 Aug 24. No abstract available.

PMID:
30144218
6.

Women prefer proactive support from providers for treatment of heavy menstrual bleeding: A qualitative study in adult women with moderate or severe Von Willebrand disease.

Eising HP, Sanders YV, de Meris J, Leebeek FWG, Meijer K.

Haemophilia. 2018 Jul 10. doi: 10.1111/hae.13552. [Epub ahead of print]

PMID:
29989261
7.

Von Willebrand disease: Clinical conundrums.

Leebeek FWG, Susen S.

Haemophilia. 2018 May;24 Suppl 6:37-43. doi: 10.1111/hae.13508. Review. No abstract available.

PMID:
29878657
8.

A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation.

Rijkers M, Saris A, Heidt S, Mulder A, Porcelijn L, Claas FHJ, Bierings R, Leebeek FWG, Jansen AJG, Vidarsson G, Voorberg J, de Haas M.

Haematologica. 2018 Oct;103(10):1741-1752. doi: 10.3324/haematol.2018.189365. Epub 2018 Jun 1.

9.

Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.

Atiq F, Meijer K, Eikenboom J, Fijnvandraat K, Mauser-Bunschoten EP, van Galen KPM, Nijziel MR, Ypma PF, de Meris J, Laros-van Gorkom BAP, van der Bom JG, de Maat MP, Cnossen MH, Leebeek FWG; WiN study group.

Br J Haematol. 2018 Jul;182(1):93-105. doi: 10.1111/bjh.15277. Epub 2018 May 16.

10.

Emerging Concepts in Immune Thrombocytopenia.

Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG, Jansen AJG.

Front Immunol. 2018 Apr 30;9:880. doi: 10.3389/fimmu.2018.00880. eCollection 2018. Review.

11.

Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin.

Abdul S, Peeters M, Brouwers E, Malfliet JJMC, Leebeek FWG, Declerck PJ, Rijken DC, Uitte de Willige S.

PLoS One. 2018 May 3;13(5):e0196911. doi: 10.1371/journal.pone.0196911. eCollection 2018.

12.

Perioperative replacement therapy in haemophilia B: An appeal to "B" more precise.

Hazendonk HCAM, Preijers T, Liesner R, Chowdary P, Hart D, Keeling D, Driessens MHE, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Mathôt RAA, Collins PW, Cnossen MH.

Haemophilia. 2018 Jul;24(4):611-618. doi: 10.1111/hae.13469. Epub 2018 Apr 29.

PMID:
29707861
13.

The level of circulating fibroblast activation protein correlates with incorporation of alpha-2-antiplasmin into the fibrin clot.

Uitte de Willige S, Malfliet JJCM, Abdul S, Leebeek FWG, Rijken DC.

Thromb Res. 2018 Jun;166:19-21. doi: 10.1016/j.thromres.2018.03.018. Epub 2018 Apr 3.

PMID:
29649768
14.

Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: a population-based study.

Wolters FJ, Boender J, de Vries PS, Sonneveld MA, Koudstaal PJ, de Maat MP, Franco OH, Ikram MK, Leebeek FW, Ikram MA.

Sci Rep. 2018 Apr 3;8(1):5474. doi: 10.1038/s41598-018-23865-7.

15.

Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment.

Hazendonk HCAM, Heijdra JM, de Jager NCB, Veerman HC, Boender J, van Moort I, Mathôt RAA, Meijer K, Laros-van Gorkom BAP, Eikenboom J, Fijnvandraat K, Leebeek FWG, Cnossen MH; “OPTI-CLOT” and “WIN” study group.

Haemophilia. 2018 May;24(3):460-470. doi: 10.1111/hae.13451. Epub 2018 Mar 24.

PMID:
29573506
16.

Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.

Preijers T, van Moort I, Fijnvandraat K, Leebeek FWG, Cnossen MH, Mathôt RAA; ‘OPTI-CLOT’ Study Group.

Thromb Haemost. 2018 Mar;118(3):514-525. doi: 10.1055/s-0038-1623531. Epub 2018 Mar 13.

PMID:
29534249
17.

Red cell distribution width in adults with congenital heart disease: A worldwide available and low-cost predictor of cardiovascular events.

Baggen VJM, van den Bosch AE, van Kimmenade RR, Eindhoven JA, Witsenburg M, Cuypers JAAE, Leebeek FWG, Boersma E, Roos-Hesselink JW.

Int J Cardiol. 2018 Jun 1;260:60-65. doi: 10.1016/j.ijcard.2018.02.118. Epub 2018 Mar 2.

18.

Incidence, predictors and clinical outcome of early bleeding events in patients undergoing a left ventricular assist device implant.

Muslem R, Caliskan K, van Thiel R, Kashif U, Akin S, Birim O, Constantinescu AA, Brugts JJ, Bunge JJH, Bekkers JA, Leebeek FWG, Bogers AJJC.

Eur J Cardiothorac Surg. 2018 Jul 1;54(1):176-182. doi: 10.1093/ejcts/ezy044.

PMID:
29481654
19.

Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients.

Schütte LM, van Hest RM, Stoof SCM, Leebeek FWG, Cnossen MH, Kruip MJHA, Mathôt RAA.

Thromb Haemost. 2018 Apr;118(4):621-629. doi: 10.1160/TH17-06-0390. Epub 2018 Feb 19.

PMID:
29458233
20.

Risk of Venous Thrombosis in Antithrombin Deficiency: A Systematic Review and Bayesian Meta-analysis.

Croles FN, Borjas-Howard J, Nasserinejad K, Leebeek FWG, Meijer K.

Semin Thromb Hemost. 2018 Jun;44(4):315-326. doi: 10.1055/s-0038-1625983. Epub 2018 Feb 16. Review.

PMID:
29452444

Supplemental Content

Loading ...
Support Center